Immunogenicity and Safety of a Meningococcal Serogroup A, C, Y and W Glycoconjugate Vaccine, ACWY-TT

Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study

(2013) Charissa Borja-Tabora et al.   BMC INFECTIOUS DISEASES

Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial

(2013) Ghassan Dbaibo et al.   DRUGS & AGING

Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study

(2013) Markus Knuf et al.   EUROPEAN JOURNAL OF PEDIATRICS

One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine Is Immunogenic in 9- to 12-Month-Old Children

(2013) Nicola P. Klein et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and Safety of a Meningococcal Quadrivalent Conjugate Vaccine in Saudi Arabian Adolescents Previously Vaccinated with One Dose of Bivalent and Quadrivalent Meningococcal Polysaccharide Vaccines: a Phase III, Controlled, Randomized, and Modified Blind-Observer Study

(2012) Yagob Al-Mazrou et al.   Clinical and Vaccine Immunology

Safety and Immunogenicity of a Meningococcal Quadrivalent Conjugate Vaccine in Five- to Eight-Year-Old Saudi Arabian Children Previously Vaccinated with Two Doses of a Meningococcal Quadrivalent Polysaccharide Vaccine

(2012) Mohamed Khalil et al.   Clinical and Vaccine Immunology

Meningococcal Quadrivalent (Serogroups A, C, W135 and Y) Tetanus Toxoid Conjugate Vaccine (Nimenrix™)

(2012) Jamie D. Croxtall et al.   DRUGS

MenACWY-TT vaccine for active immunization against invasive meningococcal disease

(2012) Vassiliki Papaevangelou et al.   Expert Review of Vaccines

The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine

(2012) Ghassan Dbaibo et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT)

(2012) Lars Østergaard et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data

(2012) Ryan T Novak et al.   LANCET INFECTIOUS DISEASES

Immunogenicity and Safety of a Booster Dose of the 10-valent Pneumococcal Haemophilus Influenzae Protein D Conjugate Vaccine Coadministered With the Tetravalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine in Toddlers

(2012) Guillermo M. Ruiz-Palacios et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Advances with vaccination againstNeisseria meningitidis

(2012) Ray Borrow   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Invasive meningococcal disease in England and Wales: Implications for the introduction of new vaccines

(2012) Shamez N. Ladhani et al.   VACCINE

Immunity to tetanus and diphtheria in the UK in 2009

(2012) Karen S. Wagner et al.   VACCINE

Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience

(2012) Mamoudou H. Djingarey et al.   VACCINE

The investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults

(2012) Mari Rose Aplasca-De Los Reyes et al.   Human Vaccines & Immunotherapeutics

Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers

(2012) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 years

(2012) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children

(2012) Markus Knuf et al.   Human Vaccines & Immunotherapeutics

The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine

(2012) Ghassan Dbaibo et al.   Human Vaccines & Immunotherapeutics

Development of a group A meningococcal conjugate vaccine,MenAfriVacTM

(2012) Carl Frasch et al.   Human Vaccines & Immunotherapeutics

Meningococcal Group C and W135 Immunological Hyporesponsiveness in African Toddlers

(2011) Helen Findlow et al.   Clinical and Vaccine Immunology

Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules

(2011) Ray Borrow et al.   Expert Review of Vaccines

Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents

(2011) Christopher J. Gill et al.   Human vaccines & immunotherapeutics

Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults

(2011) Nancy Bermal et al.   Human vaccines & immunotherapeutics

Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate Vaccine Administered to 2- to 10-year-olds Is Noninferior to a Licensed-ACWY Polysaccharide Vaccine With an Acceptable Safety Profile

(2011) Ziad A. Memish et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age

(2011) Roger Baxter et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children

(2011) Markus Knuf et al.   VACCINE

Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles–mumps–rubella–varicella vaccine during the second year of life: An open, randomized controlled trial

(2011) Timo Vesikari et al.   VACCINE

Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source

(2011) C.J. Gill et al.   VACCINE

The changing and dynamic epidemiology of meningococcal disease

(2011) Scott A. Halperin et al.   VACCINE

A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11–17 years: An open, randomised, controlled trial

(2011) Lars Østergaard et al.   VACCINE

Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity

(2010) H. Campbell et al.   Clinical and Vaccine Immunology

Safety and immunogenicity of an investigational quadrivalent meningococcal CRM197 conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America

(2010) D. Stamboulian et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Meningococcal carriage by age: a systematic review and meta-analysis

(2010) Hannah Christensen et al.   LANCET INFECTIOUS DISEASES

Advances in the Development of Vaccines againstNeisseria meningitidis

(2010) Lionel K.K. Tan et al.   NEW ENGLAND JOURNAL OF MEDICINE

High tetanus antitoxin antibody concentrations in the Netherlands: A seroepidemiological study

(2010) Anneke Steens et al.   VACCINE

Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease

(2009) Amanda C. Cohn et al.   CLINICAL INFECTIOUS DISEASES

Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs

(2009) Caroline L Trotter et al.   Expert Review of Vaccines

A Randomized Trial to Determine the Tolerability and Immunogenicity of a Quadrivalent Meningococcal Glycoconjugate Vaccine in Healthy Adolescents

(2009) Lisa A. Jackson et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Global epidemiology of meningococcal disease

(2009) Lee H. Harrison et al.   VACCINE

A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children

(2009) M. Knuf et al.   VACCINE

Immunogenicity of a Reduced Schedule of Meningococcal Group C Conjugate Vaccine Given Concomitantly with the Prevenar and Pediacel Vaccines in Healthy Infants in the United Kingdom

(2008) J. Southern et al.   Clinical and Vaccine Immunology

Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years

(2008) Lars Østergaard et al.   VACCINE